Formulation and Evaluation of Bilayer tablet of Selexipag as a Sustained release and Ambrisentan as an Immediate release for Pulmonary Arterial Hypertension treatment

The present study aimed to develop a bilayer tablet of Selexipag (a selective non-prostanoid prostacyclin receptor agonist) and Ambrisentan (selectively blocking endothelin type A receptors) to treat pulmonary arterial hypertension. The bilayer tablet was formulated to reduce the frequency of administration. The tablets were formulated using super disintegrants such as Sodium Starch Glycolate in immediate release and polymers such as ethyl cellulose and methyl cellulose in sustained release. Bilayer tablets were prepared by wet granulation. Selexipag is a selective non-prostanoid prostacyclin receptor agonist, and Ambrisentan is an endothelin receptor antagonist widely used for the treatment of Pulmonary Arterial Hypertension. (PHA). The present work involves the bi-layer tablet for the sustained release of Selexipag using Methylcellulose and ethyl cellulose as a retardant polymer and for the Immediate release of Ambrisentan using sodium starch glycolate as a super disintegrant.